{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:38Z","timestamp":1791105698170,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1124\/jpet.110.166629","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T03:24:43Z","timestamp":1268709883000},"page":"865-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease"],"prefix":"10.1016","volume":"333","author":[{"given":"Tom H.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"McIldowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Piggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.166629_bib1","unstructured":"Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Hariry S, Johns DG, Gomez-Mancilla B (2009) A randomized, controlled trial evaluating AFQ056 in reducing levodopa-induced dyskinesia in patients with Parkinson's disease (Abstract LB-05), in Proceedings of the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders; 2009; June 7\u201311; Paris, France. Movement Disorder Society, Milwaukee, WI."},{"key":"10.1124\/jpet.110.166629_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.110.166629_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.110.166629_bib4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.166629_bib5","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1523\/JNEUROSCI.23-23-08302.2003","article-title":"Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats","volume":"23","author":"Breysse","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.166629_bib6","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1523\/JNEUROSCI.22-13-05669.2002","article-title":"Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism","volume":"22","author":"Breysse","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.166629_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00702-004-0251-7","article-title":"Levodopa-induced dyskinesia in Parkinson's disease","volume":"112","author":"Brotchie","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.110.166629_bib8","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.npp.1300540","article-title":"The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety","volume":"29","author":"Busse","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.110.166629_bib9","first-page":"S60","article-title":"Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?","volume":"47","author":"Calabresi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.110.166629_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","article-title":"Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment","volume":"26","author":"Calon","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/jpet.110.166629_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.110.166629_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.110.166629_bib13","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.110.166629_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.110.166629_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/jm025570j","article-title":"3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity","volume":"46","author":"Cosford","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.110.166629_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.870050203","article-title":"A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment","volume":"5","author":"Crossman","year":"1990","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1124\/jpet.110.166629_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000131893","article-title":"Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments","volume":"60","author":"Encarnacion","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1124\/jpet.110.166629_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib20","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","article-title":"Unified Parkinson's disease rating scale","author":"Fahn","year":"1987"},{"key":"10.1124\/jpet.110.166629_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson's disease","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"10.1124\/jpet.110.166629_bib22","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1002\/mds.22021","article-title":"Levodopa-related motor complications\u2013phenomenology","volume":"23","author":"Fox","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib24","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.110.166629_bib26","article-title":"Antidyskinetic effect of AFQ056 a novel metabotropic glutamate receptor type 5 (mGluR5) antagonist in MPTP monkeys","volume":"35","author":"Gregoire","year":"2009","journal-title":"Soc Neurosci Abstr"},{"key":"10.1124\/jpet.110.166629_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pneurobio.2004.09.005","article-title":"Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases","volume":"74","author":"Gubellini","year":"2004","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.110.166629_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.166629_bib29","article-title":"The mGlu5 receptor antagonist SIB-1830 reduces l-DOPA-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"27","author":"Hill","year":"2001","journal-title":"Soc Neurosci Abstr"},{"issue":"Suppl 1","key":"10.1124\/jpet.110.166629_bib30","first-page":"64","article-title":"Patient perception of dyskinesias in Parkinson's disease","volume":"68","author":"Hung","year":"2007","journal-title":"Neurology"},{"key":"10.1124\/jpet.110.166629_bib31","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/jpet.110.166629_bib32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"10.1124\/jpet.110.166629_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1527-3458.2006.00149.x","article-title":"Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP","volume":"12","author":"Lea","year":"2006","journal-title":"CNS Drug Rev"},{"key":"10.1124\/jpet.110.166629_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.110.166629_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-8993(96)00693-2","article-title":"MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats","volume":"736","author":"Marin","year":"1996","journal-title":"Brain Res"},{"key":"10.1124\/jpet.110.166629_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00726-001-0127-1","article-title":"Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia","volume":"23","author":"Marino","year":"2002","journal-title":"Amino Acids"},{"key":"10.1124\/jpet.110.166629_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jps.21823","article-title":"Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride","volume":"99","author":"McIldowie","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.110.166629_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.110.166629_bib39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.166629_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","article-title":"The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates l-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of l-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"188","author":"Nash","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.110.166629_bib41","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00726-006-0317-y","article-title":"An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats","volume":"32","author":"Ossowska","year":"2007","journal-title":"Amino Acids"},{"key":"10.1124\/jpet.110.166629_bib43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuropharm.2005.04.002","article-title":"MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats","volume":"49","author":"Ossowska","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.166629_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1124\/jpet.110.166629_bib45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.110.166629_bib46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","article-title":"Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study","volume":"12","author":"P\u00e9chevis","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1124\/jpet.110.166629_bib47","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1212\/WNL.0b013e31819908ce","article-title":"Treatments for Parkinson disease\u2014past achievements and current clinical needs","volume":"72","author":"Poewe","year":"2009","journal-title":"Neurology"},{"key":"10.1124\/jpet.110.166629_bib48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/jpet.110.166629_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.166629_bib50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.110.166629_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.20739","article-title":"Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate","volume":"64","author":"Silverdale","year":"2010","journal-title":"Synapse"},{"key":"10.1124\/jpet.110.166629_bib52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.166629_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.903540207","article-title":"Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons","volume":"354","author":"Testa","year":"1995","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.110.166629_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"\u03b11-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.166629_bib55","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol Psychiatry"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524458151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524458151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.166629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:12:00Z","timestamp":1740017520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524458151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0022356524458151"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.166629","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.166629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}